Literature DB >> 34857017

Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).

Catherine R Hanna1, Sean M O'Cathail2, Janet S Graham2, Mark Saunders3, Leslie Samuel4, Mark Harrison5, Lynsey Devlin6, Joanne Edwards7, Daniel R Gaya8, Caroline A Kelly9, Liz-Anne Lewsley9, Noori Maka10, Paula Morrison11, Louise Dinnett9, Susan Dillon9, Jacqueline Gourlay9, Jonathan J Platt12, Fiona Thomson13, Richard A Adams14, Campbell S D Roxburgh15.   

Abstract

Entities:  

Year:  2021        PMID: 34857017      PMCID: PMC8638219          DOI: 10.1186/s13014-021-01941-z

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


× No keyword cloud information.

Correction to: Radiat Oncol (2021) 16:163. https://doi.org/10.1186/s13014-021-01888-1

After publication of this article [1], the authors reported that the Funding information section was incomplete. The following should have been added: “This work was supported by CRUK (Grant Number C61974/A2429).” The original article [1] has been updated.
  1 in total

1.  Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).

Authors:  Catherine R Hanna; Sean M O'Cathail; Janet S Graham; Mark Saunders; Leslie Samuel; Mark Harrison; Lynsey Devlin; Joanne Edwards; Daniel R Gaya; Caroline A Kelly; Liz-Anne Lewsley; Noori Maka; Paula Morrison; Louise Dinnett; Susan Dillon; Jacqueline Gourlay; Jonathan J Platt; Fiona Thomson; Richard A Adams; Campbell S D Roxburgh
Journal:  Radiat Oncol       Date:  2021-08-26       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.